Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099235 | 1.00 | ALOX5 (0.35) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL13813449 | 0.75 | ALOX5 (0.36) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL13799997 | 0.74 | GPR3 (0.32) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL12425595 | 0.70 | GPR3 (0.46) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL4094454 | 0.70 | HCRTR1 (0.32) | — | |
| SCHEMBL4093915 | 0.69 | GPR3 (0.44) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL28667430 | 0.68 | — | — | |
| SCHEMBL5689250 | 0.67 | ALOX5 (0.73) | ALOX5 | |
| SCHEMBL4099685 | 0.65 | GPR3 (0.40) | ALOX5GPR3PRNPRXFP1 | |
| SCHEMBL22320228 | 0.65 | GPR3 (0.40) | ALOX5GPR3PRNPRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | ALOX5 2681/4885GPR3 4277/4885PRNP 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.